Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2021.613070 http://scihub22266oqcxt.onion/10.3389/fimmu.2021.613070 33815368!8012541!33815368     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Immunol 2021 ; 12 (ä): 613070 Nephropedia Template TP {{tp|p=33815368|t=2021. Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients |pdf=|usr=}}{{33815368}} gab.com Text Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33815368 #FOAvip Lack of specific antiviral treatment for COVID-19 has resulted in long hospitalizations and high mortality rate. By harnessing the regulatory effects of adenosine on inflammatory mediators, we have instituted a new therapeutic treatment with inhaled adenosine in COVID-19 patients, with the aim of reducing inflammation, the onset of cytokine storm, and therefore to improve prognosis. The use of inhaled adenosine in COVID19 patients has allowed reduction of length of stay, on average 6 days. This result is strengthened by the decrease in SARS-CoV-2 positive days. In treated patients compared to control, a clear improvement in PaO(2)/FiO(2) was observed together with a reduction in inflammation parameters, such as the decrease of CRP level. Furthermore, the efficacy of inhaled exogenous adenosine led to an improvement of the prognosis indices, NLR and PLR. The treatment seems to be safe and modulates the immune system, allowing an effective response against the viral infection progression, reducing length of stay and inflammation parameters. Twit Text FOAVip Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33815368 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33815368 #FOAvip English Wikipedia <ref>{{Cite pmid|33815368}}</ref> Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients #MMPMID33815368 Caracciolo M; Correale P; Mangano C; Foti G; Falcone C; Macheda S; Cuzzola M; Conte M; Falzea AC; Iuliano E; Morabito A; Caraglia M; Polimeni N; Ferrarelli A; Labate D; Tescione M; Di Renzo L; Chiricolo G; Romano L; De Lorenzo A Front Immunol 2021[]; 12 (ä): 613070 PMID33815368show ga Lack of specific antiviral treatment for COVID-19 has resulted in long hospitalizations and high mortality rate. By harnessing the regulatory effects of adenosine on inflammatory mediators, we have instituted a new therapeutic treatment with inhaled adenosine in COVID-19 patients, with the aim of reducing inflammation, the onset of cytokine storm, and therefore to improve prognosis. The use of inhaled adenosine in COVID19 patients has allowed reduction of length of stay, on average 6 days. This result is strengthened by the decrease in SARS-CoV-2 positive days. In treated patients compared to control, a clear improvement in PaO(2)/FiO(2) was observed together with a reduction in inflammation parameters, such as the decrease of CRP level. Furthermore, the efficacy of inhaled exogenous adenosine led to an improvement of the prognosis indices, NLR and PLR. The treatment seems to be safe and modulates the immune system, allowing an effective response against the viral infection progression, reducing length of stay and inflammation parameters. |*COVID-19 Drug Treatment[MESH] |Adenosine/*pharmacology/therapeutic use[MESH] |Adult[MESH] |Aged[MESH] |Anti-Bacterial Agents/administration & dosage[MESH] |Azithromycin/administration & dosage[MESH] |COVID-19/diagnostic imaging/physiopathology[MESH] |Case-Control Studies[MESH] |Cytochrome P-450 CYP3A Inhibitors/administration & dosage[MESH] |Cytokine Release Syndrome/physiopathology[MESH] |Enzyme Inhibitors/administration & dosage[MESH] |Female[MESH] |Heparin/administration & dosage[MESH] |Hospitalization[MESH] |Humans[MESH] |Hydroxychloroquine/administration & dosage[MESH] |Inflammation/drug therapy[MESH] |Lopinavir/administration & dosage[MESH] |Male[MESH] |Middle Aged[MESH] |Prognosis[MESH]Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COV(epmc).pdf DeepDyve Pubget Overpricing